Country-specific differences in bacterial antibiotic resistances cause variability in recommendations given in different countries. Mutually approved national expert and hospital-specific practices are therefore beneficial. Selection of the best prophylactic antimicrobial drug and correct timing of drug dosing are of high significance. In the light of our questionnaire survey prophylactic practices are relatively consistent in Finland. Hospitals have operation-specific recommendations on prophylaxis, but adherence to them is scarcely monitored. In fact, hospitals should invest in such monitoring systems.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Rationale and Logistics of Continuous Infusion Cephalosporin Antibiotics.
Pharmacy (Basel)
December 2024
Department of Pharmacy, Prisma Health Richland, 5 Medical Park Drive, Columbia, SC 29203, USA.
Cephalosporins have traditionally been administered as an intermittent infusion. With the knowledge that cephalosporins demonstrate a time-dependent pharmacodynamic profile, administration via continuous infusion may provide more effective antibiotic exposure for successful therapy. Proposed benefits of administration via continuous infusion include less IV manipulation, decreased potential for antibiotic resistance, and potential cost savings.
View Article and Find Full Text PDFFumagillin Shortage: How to Treat Microsporidiosis in Solid Organ Transplant Recipients in 2024?
Transpl Int
December 2024
Service de Parasitologie-Mycologie, 3IHP, Inserm U1071, M2iSH, USC-INRAE 1382, Université Clermont Auvergne, CHU Clermont-Ferrand, Clermont-Ferrand, France.
Unlabelled: Intestinal microsporidiosis caused by is an opportunistic infection that especially affects solid organ transplant (SOT) recipients. Management revolves around tapering the immunosuppressive regimen and/or using a specific anti-microsporidia treatment, but only fumagillin has demonstrated efficacy for treatment of this infection. Since fumagillin has been commercially discontinued, nitazoxanide is increasingly being used in this indication.
View Article and Find Full Text PDFAutomated surveillance for surgical site infections (SSI) in hospitals and surveillance networks-expert perspectives for implementation.
Antimicrob Resist Infect Control
December 2024
Centre for Infectious Diseases Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
Background: This work aims at providing practical recommendations for implementing automated surveillance (AS) of surgical site infections (SSI) in hospitals and surveillance networks. It also provides an overview of the steps, choices, and obstacles that need to be taken into consideration when implementing such surveillance. Hands-on experience with existing automated surveillance systems of SSI (AS SSI systems) in Denmark, France, the Netherlands and Spain is described regarding trend monitoring, benchmarking, quality control, and research for surveillance purposes.
View Article and Find Full Text PDFPilot study of topical ruxolitinib demonstrates efficacy and blunting of heterogeneous inflammatory processes in mild hidradenitis suppurativa.
Br J Dermatol
December 2024
The Pennsylvania State University College of Medicine, Department of Dermatology, Hershey, PA, USA.
Background: Therapeutic options for mild hidradenitis suppurativa (HS) represent a significant gap in the current treatment landscape, with no FDA approved therapies for early stage HS. Topical JAnus Kinase inhibitors (JAKi) are a compelling option due to the known upregulation of inflammatory JAK signaling in HS lesions and the recent success of systemic JAKi for moderate to severe HS.
Objectives: This is a pilot, single-site, open-label, prospective 24-week clinical trial with topical ruxolitinib (NCT04414514).
Lupus nephritis randomised controlled trials: evidence gaps and under-represented groups.
Lupus Sci Med
December 2024
Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Objective: We performed a scoping review of randomised clinical trials (RCTs) assessing pharmacological therapies for the initial management of lupus nephritis (LN), focusing on study design, included populations and outcome definitions, to assess the generalisability of their results and identify gaps in the evidence.
Methods: RCTs evaluating pharmacological interventions for the initial therapy of LN published between 2000 and 2024 were evaluated. Extracted variables included study design, selection criteria, outcome definitions, populations recruited and clinical characteristics of participants.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!